查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1889212

2032年解剖病理学市场预测：按产品、技术、应用、最终用户和地区分類的全球分析

Anatomic Pathology Market Forecasts to 2032 - Global Analysis By Product (Instruments, Consumables, and Services), Technique, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2025 年，全球解剖病理学市场规模将达到 387.8 亿美元，到 2032 年将达到 841.4 亿美元，预测期内复合年增长率为 11.7%。

解剖病理学是一门医学专科，它透过检查从人体取出的组织、器官和细胞来诊断疾病。解剖病理学家运用宏观检查、微观分析和先进的实验室技术，识别肿瘤、感染疾病和结构改变等异常情况。解剖病理学家在指南各种医学学科的临床决策方面发挥着至关重要的作用，他们提供精准的诊断信息，支持患者管理、治疗方案製定和疾病监测。

根据世界卫生组织（世卫组织）估计，2022 年全球将新增 2,000 万例癌症病例，并有 970 万人死于癌症。

扩大个人化医疗的普及范围

随着治疗方案越来越注重个人化，临床医师越来越依赖精准的组织分析来指南决策。分子病理学和基于生物标记的检测技术正在不断发展，提高了治疗选择的精确度。数位病理学与人工智慧工具的融合，使得诊断更加快速、深入。医疗机构正加大对专业病理服务的投入，以支持个人化治疗策略。这种向精准医疗的转变预计将持续推动市场的长期成长。

熟练病理学家和技术人员短缺

由于工作量增加和专科医生短缺，许多医疗机构都面临延误问题。随着诊断程序日益复杂，对专业技能的需求也更加迫切。培训计画的扩展速度未能跟上诊断量的成长，这会导致检测结果的周转时间延长，并影响临床决策。这种人才短缺问题对全球医疗机构的运作构成了持续的挑战。

对伴随诊断（CDx）的需求不断增长

标靶治疗的日益普及加速了病理解剖学领域对伴随诊断的需求。这些检测能够根据患者的生物标记，帮助确定是否适合接受特定药物治疗。不断增长的肿瘤药物研发管线进一步推动了伴随诊断在临床工作流程中的整合。组织分析技术的进步提高了预测性检测的准确性。全球市场对伴随诊断相关疗法的监管核准也不断扩大。这种日益增长的需求为病理服务提供者和诊断研发公司带来了巨大的机会。

替代产品和技术的威胁

由于液态生物检体具有非侵入性和快速出结果的优点，因此备受关注。影像技术的进步也对传统的组织检测提出了挑战。一些医疗机构可能会转向这些替代方法以提高诊断效率。科技的快速创新有可能进一步降低对传统病理学方法的依赖。这种竞争环境可能会限制那些未能适应发展趋势的医疗机构的发展。

新冠疫情的影响：

新冠疫情扰乱了许多实验室的检查室流程，导致择期诊断检测延误。病理科面临病例量减少和常规检测延误的双重困境。然而，这场危机加速了数位化病理和远距离诊断审核模式的普及。检查室纷纷投资自动化和云端基础系统，以维持服务的连续性。疫情后的战略重点在于建立更强大的基础设施、提高人员配备的柔软性以及运用技术手段进行诊断。

预计在预测期内，服务业细分市场将占据最大的市场份额。

预计在预测期内，服务领域将占据最大的市场份额，这主要得益于诊断检测外包给专业病理检查室的趋势日益增长。医疗机构依赖这些服务进行先进的分子和解剖病理分析。服务供应商提供全面的检测流程，无需医院投资昂贵的设备。数位病理和快速报告功能也进一步推动了市场需求。

预计在预测期内，医院和门诊手术中心（ASC）板块的复合年增长率将最高。

预计在预测期内，医院和门诊手术中心（ASC）领域将实现最高增长率，因为患者入院人数的增加和手术量的扩大推动了对院内病理支持的需求。许多医疗机构正在采用数位化病理平台来加速诊断决策。对现代化检查室基础设施的投资正在帮助医院减少对外部诊断中心的依赖。人工智慧工具的应用正在提高工作流程的效率和准确性。

占比最大的地区：

在预测期内，北美预计将占据最大的市场份额，这主要得益于其强大的医疗基础设施和庞大的诊断检测量。该地区受益于数位病理学和人工智慧驱动的诊断工具的早期应用。对癌症研究和生物标誌物开发的大规模投资进一步推动了市场成长。有利的报销政策也促进了先进病理服务的普及。

复合年增长率最高的地区：

预计亚太地区在预测期内将实现最高的复合年增长率，这主要得益于医疗保健体系的扩展和人们对疾病早期诊断意识的提高。中国和印度等国家正大力投资现代检测技术。癌症发生率的上升正在加速先进病理服务的普及。公私部门的合作正在提高新兴市场的诊断可及性。

免费客製化服务：

购买此报告的客户可享有以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要企业SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，提供主要国家的市场估算和预测，以及复合年增长率（註：可行性需确认）。
  • 竞争基准化分析
    • 基于产品系列、地域覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 摘要
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球解剖病理学市场（依产品划分）

  • 装置
    • 切片机
    • 染色设备
    • 组织处理系统
  • 消耗品
    • 试剂
    • 幻灯片盒
    • 成套工具
  • 服务
    • 解剖病理服务
    • 免疫组织化学服务
    • 细胞病理服务
    • 数位病理服务

6. 全球解剖病理学市场（依技术划分）

  • 组织学
  • 血液凝固检验
  • 免疫组织化学（IHC）
  • 血清学/免疫学
  • 分子病理学
  • 一般血液检查

7. 全球解剖病理学市场（按应用划分）

  • 疾病诊断
    • 肿瘤学
    • 感染疾病
    • 慢性病
  • 药物发现与开发
  • 其他用途

8. 全球解剖病理学市场（依最终用户划分）

  • 医院和门诊手术中心（ASC）
  • 临床和诊断检查室
  • 研究所
  • 血库
  • 其他最终用户

9. 全球解剖病理学市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十一章 企业概况

  • Roche Diagnostics
  • Becton, Dickinson and Company（BD）
  • Thermo Fisher Scientific
  • Hologic Inc.
  • Agilent Technologies
  • PerkinElmer
  • Danaher Corporation
  • Abbott Laboratories
  • Sakura Finetek Japan
  • Merck KGaA
  • BioGenex Laboratories
  • Cardinal Health
  • Quest Diagnostics
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
Product Code: SMRC32672

According to Stratistics MRC, the Global Anatomic Pathology Market is accounted for $38.78 billion in 2025 and is expected to reach $84.14 billion by 2032 growing at a CAGR of 11.7% during the forecast period. Anatomic pathology is a medical specialty focused on diagnosing diseases by examining tissues, organs, and cells removed from the body. It involves techniques such as gross examination, microscopic analysis, and advanced lab testing to identify abnormalities, including tumors, infections, and structural changes. Anatomic pathologists play a crucial role in guiding clinical decisions by providing precise diagnostic information that supports patient management, treatment planning, and disease monitoring across various medical fields.

According to the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths worldwide.

Market Dynamics:

Driver:

Growing adoption of personalized medicine

As treatments become more tailored to individual patient profiles, clinicians rely heavily on precise tissue analysis to guide decision-making. Molecular pathology and biomarker-driven testing are expanding, enhancing the accuracy of therapeutic selections. Integration of digital pathology and AI-based tools is enabling faster and more detailed diagnostic insights. Healthcare providers are increasingly investing in specialized pathology services to support individualized treatment strategies. This shift toward precision care is expected to continue strengthening the market's long-term growth.

Restraint:

Shortage of skilled pathologists and technicians

Many healthcare facilities face delays due to high workloads and limited expert availability. The growing complexity of diagnostic procedures further increases the demand for specialized skill sets. Training programs are not expanding quickly enough to meet rising diagnostic volumes. As a result, turnaround times may lengthen, affecting clinical decision-making. This workforce gap continues to pose operational challenges for institutions worldwide.

Opportunity:

Rising demand for companion diagnostics (CDx)

Increasing adoption of targeted therapies is accelerating the need for companion diagnostics in anatomic pathology. These tests help determine the suitability of specific drugs based on individual patient biomarkers. Growth in oncology pipelines is further driving CDx integration into clinical workflows. Advancements in tissue profiling technologies are enhancing the accuracy of predictive testing. Regulatory approvals for CDx-linked treatments are expanding across global markets. This rising demand is opening significant opportunities for pathology providers and diagnostic developers.

Threat:

Threat of substitute products/techniques

Liquid biopsy methods are gaining attention due to their non-invasive nature and faster turnaround times. Advancements in imaging-based diagnostics are also challenging traditional tissue examination. Some healthcare providers may shift toward these substitutes to streamline diagnostics. Rapid technological innovations could further reduce reliance on conventional pathology approaches. This competitive environment may limit growth for providers who do not adapt to evolving trends.

Covid-19 Impact:

The COVID-19 pandemic disrupted laboratory workflows and slowed elective diagnostic procedures in many facilities. Pathology departments faced reduced case volumes and delays in routine testing. However, the crisis accelerated digital pathology adoption and remote diagnostic review models. Laboratories invested in automation and cloud-based systems to maintain service continuity. Post-pandemic strategies now emphasize stronger infrastructure, workforce flexibility, and technology-enabled diagnostics.

The services segment is expected to be the largest during the forecast period

The services segment is expected to account for the largest market share during the forecast period, driven by rising outsourcing of diagnostic testing to specialized pathology laboratories. Healthcare providers rely on these services for advanced molecular and histopathological analyses. Service providers offer comprehensive testing workflows without requiring hospitals to invest in costly equipment. Their capabilities in digital pathology and rapid reporting further drive demand.

The hospitals & ambulatory surgical centers (ASCs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals & ambulatory surgical centers (ASCs) segment is predicted to witness the highest growth rate, due to rising patient admissions and expanding surgical procedures are increasing the demand for onsite pathology support. Many facilities are adopting digital pathology platforms to speed up diagnostic decisions. Investments in modern laboratory infrastructure are helping hospitals reduce reliance on external diagnostic centers. Adoption of AI-enabled tools is improving workflow efficiency and accuracy.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to strong healthcare infrastructure and high diagnostic testing volumes support this dominance. The region benefits from early adoption of digital pathology and AI-driven diagnostic tools. Large investments in cancer research and biomarker development further strengthen market growth. Favorable reimbursement policies encourage widespread use of advanced pathology services.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to expanding healthcare systems and rising awareness of early disease diagnosis are fueling demand. Countries such as China and India are investing heavily in modern laboratory technologies. Growing incidences of cancer are accelerating the adoption of advanced pathology services. Public and private sector collaborations are improving diagnostic accessibility in emerging markets.

Key players in the market

Some of the key players in Anatomic Pathology Market include Roche Dia, Becton, Di, Thermo Fi, Hologic In, Agilent Te, PerkinElm, Danaher Co, Abbott Lab, Sakura Fin, Merck KGa, BioGenex, Cardinal H, Quest Dia, Laborator, and NeoGeno.

Key Developments:

In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc., a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio's pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients.

In April 2025, Thermo Fisher Scientific has introduced the Thermo Scientific(TM) Krios(TM) 5 Cryo-TEM. This next-generation, atomic-resolution platform leverages enhanced optics and AI-enabled automation to study molecular structures and interactions at a throughput and fidelity that was previously unattainable.

Products Covered:

  • Instruments
  • Consumables
  • Services

Techniques Covered:

  • Histology
  • Coagulation Tests
  • Immunohistochemistry (IHC)
  • Serology & Immunology
  • Molecular Pathology
  • Blood Routine Examination

Applications Covered:

  • Disease Diagnosis
  • Drug Discovery & Development
  • Other Applications

End Users Covered:

  • Hospitals & Ambulatory Surgical Centers (ASCs)
  • Clinical & Diagnostic Laboratories
  • Research Institutes
  • Blood Banks
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Anatomic Pathology Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
    • 5.2.1 Microtomes
    • 5.2.2 Stainers
    • 5.2.3 Tissue Processing Systems
  • 5.3 Consumables
    • 5.3.1 Reagents
    • 5.3.2 Slides & Cassettes
    • 5.3.3 Kits
  • 5.4 Services
    • 5.4.1 Histopathology Services
    • 5.4.2 Immunohistochemistry Services
    • 5.4.3 Cytopathology Services
    • 5.4.4 Digital Pathology Services

6 Global Anatomic Pathology Market, By Technique

  • 6.1 Introduction
  • 6.2 Histology
  • 6.3 Coagulation Tests
  • 6.4 Immunohistochemistry (IHC)
  • 6.5 Serology & Immunology
  • 6.6 Molecular Pathology
  • 6.7 Blood Routine Examination

7 Global Anatomic Pathology Market, By Application

  • 7.1 Introduction
  • 7.2 Disease Diagnosis
    • 7.2.1 Oncology
    • 7.2.2 Infectious Diseases
    • 7.2.3 Chronic Conditions
  • 7.3 Drug Discovery & Development
  • 7.4 Other Applications

8 Global Anatomic Pathology Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Ambulatory Surgical Centers (ASCs)
  • 8.3 Clinical & Diagnostic Laboratories
  • 8.4 Research Institutes
  • 8.5 Blood Banks
  • 8.6 Other End Users

9 Global Anatomic Pathology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Roche Diagnostics
  • 11.2 Becton, Dickinson and Company (BD)
  • 11.3 Thermo Fisher Scientific
  • 11.4 Hologic Inc.
  • 11.5 Agilent Technologies
  • 11.6 PerkinElmer
  • 11.7 Danaher Corporation
  • 11.8 Abbott Laboratories
  • 11.9 Sakura Finetek Japan
  • 11.10 Merck KGaA
  • 11.11 BioGenex Laboratories
  • 11.12 Cardinal Health
  • 11.13 Quest Diagnostics
  • 11.14 Laboratory Corporation of America Holdings
  • 11.15 NeoGenomics Laboratories

List of Tables

  • Table 1 Global Anatomic Pathology Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Anatomic Pathology Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Anatomic Pathology Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Anatomic Pathology Market Outlook, By Microtomes (2024-2032) ($MN)
  • Table 5 Global Anatomic Pathology Market Outlook, By Stainers (2024-2032) ($MN)
  • Table 6 Global Anatomic Pathology Market Outlook, By Tissue Processing Systems (2024-2032) ($MN)
  • Table 7 Global Anatomic Pathology Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 8 Global Anatomic Pathology Market Outlook, By Reagents (2024-2032) ($MN)
  • Table 9 Global Anatomic Pathology Market Outlook, By Slides & Cassettes (2024-2032) ($MN)
  • Table 10 Global Anatomic Pathology Market Outlook, By Kits (2024-2032) ($MN)
  • Table 11 Global Anatomic Pathology Market Outlook, By Services (2024-2032) ($MN)
  • Table 12 Global Anatomic Pathology Market Outlook, By Histopathology Services (2024-2032) ($MN)
  • Table 13 Global Anatomic Pathology Market Outlook, By Immunohistochemistry Services (2024-2032) ($MN)
  • Table 14 Global Anatomic Pathology Market Outlook, By Cytopathology Services (2024-2032) ($MN)
  • Table 15 Global Anatomic Pathology Market Outlook, By Digital Pathology Services (2024-2032) ($MN)
  • Table 16 Global Anatomic Pathology Market Outlook, By Technique (2024-2032) ($MN)
  • Table 17 Global Anatomic Pathology Market Outlook, By Histology (2024-2032) ($MN)
  • Table 18 Global Anatomic Pathology Market Outlook, By Coagulation Tests (2024-2032) ($MN)
  • Table 19 Global Anatomic Pathology Market Outlook, By Immunohistochemistry (IHC) (2024-2032) ($MN)
  • Table 20 Global Anatomic Pathology Market Outlook, By Serology & Immunology (2024-2032) ($MN)
  • Table 21 Global Anatomic Pathology Market Outlook, By Molecular Pathology (2024-2032) ($MN)
  • Table 22 Global Anatomic Pathology Market Outlook, By Blood Routine Examination (2024-2032) ($MN)
  • Table 23 Global Anatomic Pathology Market Outlook, By Application (2024-2032) ($MN)
  • Table 24 Global Anatomic Pathology Market Outlook, By Disease Diagnosis (2024-2032) ($MN)
  • Table 25 Global Anatomic Pathology Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 26 Global Anatomic Pathology Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 27 Global Anatomic Pathology Market Outlook, By Chronic Conditions (2024-2032) ($MN)
  • Table 28 Global Anatomic Pathology Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
  • Table 29 Global Anatomic Pathology Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 30 Global Anatomic Pathology Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Anatomic Pathology Market Outlook, By Hospitals & Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 32 Global Anatomic Pathology Market Outlook, By Clinical & Diagnostic Laboratories (2024-2032) ($MN)
  • Table 33 Global Anatomic Pathology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 34 Global Anatomic Pathology Market Outlook, By Blood Banks (2024-2032) ($MN)
  • Table 35 Global Anatomic Pathology Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.